These studies are relevant from a clinical standpoint because high levels of Cdc7 and Dbf4 expression have been reported in several types of cancers (Bonte et al. 2008) and this correlates with accelerated progression through the cell cycle, mutation of p53, resistance to DNA damaging agents and chemotherapy, and poor survival rates (Montagnoli et al. 2004; Bonte et al. 2008; Kulkarni et al. 2009; Rodriguez-Acebes et al. 2010; Hou et al. 2012; Cheng et al. 2013). This evidence concerns the gene TP53 and cancer.